St. Jude Medical Announces FDA Approval Of Company's First Radiofrequency Wireless ICD And CRT-D Heart Failure Devices (Medical News Today)
St. Jude Medical, Inc. (NYSE:STJ) announced U.S. Food and Drug Administration (FDA) approval of its first radiofrequency (RF) wireless devices to treat patients with heart failure and with potentially lethal heart arrhythmias. [click link for full article]

Review combination drugs on lines of US FDA: medical expert (PharmaBiz)
Even as some half hearted efforts are on in the country to weed out irrational combination drugs from the market, experts in the medical field have called for a comprehensive review of all the combination drugs available in the country on the lines of the US FDA action way back in 1970.

Pipex Pharmaceuticals Plans November NDA Filing for COPREXA Based on Pre-NDA Meetings With FDA (Marketwire via Yahoo! Finance)
Pipex Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of neurologic and fibrotic diseases, announced today that it completed a series of pre-NDA meetings with the FDA yesterday regarding its lead drug candidate, COPREXA, and that in November Pipex plans to submit its New Drug Application for COPREXA for the treatment ...